Transforming discoveries into better patient care
"Our patients at Hennepin Healthcare benefit from the research we do at the Hennepin Healthcare Research Institute by getting access to newer medications and new treatments that are available through our research programs."
~ Ajay Israni, MD
Hennepin Healthcare Research Institute President
At the Hennepin Healthcare Research Institute (HHRI), we've been investigating the causes of and potential treatments for diseases since 1952. We support and oversee medical research at HCMC, Hennepin Healthcare's acute care and teaching hospital. Our research topics are diverse with a focus on four areas: Acute Care/Trauma, Addiction, Health Services and Infectious Diseases (HIV/AIDS). Innovative discoveries made at HHRI improve the lives of patients in our local community and across the globe.
HHRI Research Highlights
Hennepin Healthcare collaborates with Mayo Clinic on convalescent plasma protocol as a therapeutic treatment for COVID-19 patients
Minneapolis, Minn. – Hennepin Healthcare Research Institute (HHRI) is collaborating with the Mayo Clinic to engage in a clinical protocol using convalescent plasma as a therapeutic treatment for COVID-19 patients. Convalescent plasma has appeared to be of benefit for the treatment of certain infectious diseases, including infections from respiratory viruses. This clinical protocol seeks to…Read More
Hennepin Healthcare partners with University of Minnesota on COVID-19 clinical trials of blood pressure drug losartan
Hennepin Healthcare Research Institute (HHRI) and University of Minnesota Medical School researchers have begun enrolling patients in newly launched clinical trials involving a blood pressure medication, losartan, as a potential treatment for those recently diagnosed with COVID-19. Both studies are multi-site trials, one for patients requiring hospitalization and the other for diagnosed patients who do…Read More
Hennepin Healthcare launches two clinical trials to study the investigational antiviral drug remdesivir to treat hospitalized patients with COVID-19
Minneapolis, Minn. – April 9, 2020 – The Hennepin Healthcare Research Institute (HHRI) has launched two clinical trials to study the safety and efficacy of remdesivir to treat hospitalized patients diagnosed with moderate or severe COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Hennepin Healthcare is a clinical site for the international multi-center randomized…Read More
No matter the amount, your donation to medical research makes a big difference in
improving patient care and enhancing lives.
Support advancements in medicine. Donate to HHRI today.